1. Scrip
  2. >>Business
  3. >>Earnings

Incyte Tosses IO Candidates To Focus On High-Value Pipeline Assets

 
• By Alaric DeArment

The drug maker’s next-generation JAK1 inhibitor povorcitinib has an addressable market potentially worth more than $3bn if it wins approval in hidradenitis suppurativa and vitiligo.

Incyte shuffled its pipeline in Q2, discontinuing several IO programs • Source: Shutterstock

Incyte Corporation is jettisoning a suite of immunotherapy programs to focus on more high-value assets in its pipeline, particularly as its flagship drug Jakafi (ruxolitinib) gets closer to losing market exclusivity. The pipeline shake-up includes a number of immuno-oncology drug candidates.

The Wilmington, DE-based drug maker reported its second quarter earnings on 30 July, posting $1bn in revenue that represented 9%...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

In Brief: Concentra Snaps Up Struggling IGM Biosciences In Latest Biotech Deal

 
• By Sushmita Panda

Concentra Biosciences is acquiring struggling IGM Biosciences for $1.25 per share plus a contingent value right, with the deal expected to close in August 2025.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: AbbVie’s big autoimmune CAR-T play; In Vivo CAR-T interest grows; China deal perspectives from BIO; global pharma interest in Korea undeterred; and a look at the biggest drug sales disappointments.

Second Quarter M&A Activity Looks Like More Of The Same, Mostly

 
• By Joseph Haas

The biopharma sector booked nearly the same number of acquisitions in each of the past two quarters, according to Evaluate data, but there are some encouraging signs in Q2.